People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sunesis Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $38.5M | $969.1M | 2010 |
Dayton K. Misfeldt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dayton K. Misfeldt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Hurwitz | 1 | 9 |
| Dayton Misfeldt | 1 | 4 |
| JAMES W. YOUNG | 1 | 3 |
| Matthew K. Fust | 1 | 3 |
| Homer L. Pearce | 1 | 3 |
| Eric H. Bjerkholt | 1 | 2 |
| Eric H. Bjerholt | 1 | 1 |
| Steven B. Ketchum | 1 | 1 |
| Daniel N., Jr. Swisher | 1 | 1 |
| David C. Stump | 1 | 1 |
| Helen Susan Kim | 1 | 1 |
| Steven H. Ketchum | 1 | 1 |
| Ed K. Hurwitz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.